Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03999736 · ClinicalTrials.gov registry record · Phase 1
Biomarkers of Response to Treatment With Frontal Cortex Stimulation for Anxious Depression
A Phase 1 study, sponsored by Mclean Hospital.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT03999736 is a Phase 1 study that was terminated before completion, run by Mclean Hospital. The registered enrollment target is 1 participants.
The verdict
NCT03999736, a Phase 1 study, was terminated before completion, sponsored by Mclean Hospital.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is an add-on study to an existing multimodal neuroimaging study in MDD by investigating the acute effects of DLPFC tDCS on threat vigilance in 24-44 patients with MDD, as part of an open-label treatment intervention study. Behavioral and neural measures of threat vigilance will be taken acutely and investigated as predictors of subsequent treatment response to a four-week, fourteen-session DLPFC tDCS intervention, using a novel home-tDCS protocol. The design takes advantage of an existing rich set of candidate baseline behavioral, neural and molecular measures from the existing neuroimaging study, which could be used to predict treatment response to tDCS and thereby, aid future patient selection for clinical trials.
Interventions
- DEVICE transcranial direct current stimulation using a Soterix mini-CT device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-02-13 |
| Est. Completion | 2021-02-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03999736
The ClinicalTrials.gov registry entry for NCT03999736 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mclean Hospital, which has 140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which transcranial direct current stimulation using a Soterix mini-CT device is the first listed.
NCT03999736 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03999736 about?
NCT03999736 is a clinical study titled "Biomarkers of Response to Treatment With Frontal Cortex Stimulation for Anxious Depression". This is an add-on study to an existing multimodal neuroimaging study in MDD by investigating the acute effects of DLPFC tDCS on threat vigilance in 24-44 patients with MDD, as part of an open-label treatment intervention study. Behavioral and neural measures of threat vigilance will be taken acutely...
What is the current status of trial NCT03999736?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2020-02-13. Estimated completion is 2021-02-09.
What interventions are being tested in trial NCT03999736?
The interventions under investigation include: transcranial direct current stimulation using a Soterix mini-CT device (DEVICE).
Who is sponsoring clinical trial NCT03999736?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.